[go: up one dir, main page]

MA33531B1 - Composés de benzoxazépine inhibiteurs de pi3k et leurs procédés d'utilisation - Google Patents

Composés de benzoxazépine inhibiteurs de pi3k et leurs procédés d'utilisation

Info

Publication number
MA33531B1
MA33531B1 MA34637A MA34637A MA33531B1 MA 33531 B1 MA33531 B1 MA 33531B1 MA 34637 A MA34637 A MA 34637A MA 34637 A MA34637 A MA 34637A MA 33531 B1 MA33531 B1 MA 33531B1
Authority
MA
Morocco
Prior art keywords
benzoxazepine
methods
pi3k inhibitors
formula
compounds
Prior art date
Application number
MA34637A
Other languages
Arabic (ar)
English (en)
Inventor
Nicole Blaquiere
Steven Do
Danette Dudley
Adrian J Folkes
Robert Heald
Timothy Heffron
Mark Jones
Aleksandr Kolesnikov
Chudi Ndubaku
Alan G Olivero
Stephen Price
Steven Staben
Lan Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43037239&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33531(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33531B1 publication Critical patent/MA33531B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION PORTE SUR DES COMPOSÉS DE BENZOXAZÉPINE DE FORMULE (I) Y COMPRIS LES STÉRÉOISOMÈRES, ISOMÈRES GÉOMÉTRIQUES, TAUTOMÈRES OU SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CEUX-CI, DANS LAQUELLE FORMULE : Z1 REPRÉSENTE CR1 OU N; Z2 REPRÉSENTE CR2 OU N; Z3 REPRÉSENTE CR3 OU N; Z4 REPRÉSENTE CR4 OU N; ET B REPRÉSENTE UN NOYAU PYRAZOLYLE, IMIDAZOLYLE OU TRIAZOLYLE, LESQUELS COMPOSÉS ONT UNE ACTIVITÉ ANTICANCÉREUSE ET, PLUS SPÉCIFIQUEMENT, INHIBENT L'ACTIVITÉ DE LA PI3-KINASE.
MA34637A 2009-09-28 2012-02-15 Composés de benzoxazépine inhibiteurs de pi3k et leurs procédés d'utilisation MA33531B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24638109P 2009-09-28 2009-09-28
US33068510P 2010-05-03 2010-05-03
PCT/EP2010/064208 WO2011036280A1 (fr) 2009-09-28 2010-09-27 Composés de benzoxazépine inhibiteurs de pi3k et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
MA33531B1 true MA33531B1 (fr) 2012-08-01

Family

ID=43037239

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34637A MA33531B1 (fr) 2009-09-28 2012-02-15 Composés de benzoxazépine inhibiteurs de pi3k et leurs procédés d'utilisation

Country Status (31)

Country Link
US (7) US8242104B2 (fr)
EP (3) EP2845592A1 (fr)
JP (2) JP5540101B2 (fr)
KR (1) KR101428346B1 (fr)
CN (2) CN102762576B (fr)
AR (1) AR078187A1 (fr)
AU (1) AU2010299816C1 (fr)
BR (1) BR112012006807A2 (fr)
CA (1) CA2772691C (fr)
CL (1) CL2012000754A1 (fr)
CO (1) CO6491026A2 (fr)
CR (1) CR20120121A (fr)
DK (1) DK2483278T3 (fr)
EC (1) ECSP12011755A (fr)
ES (2) ES2570569T3 (fr)
HR (1) HRP20140229T1 (fr)
IL (2) IL217558A (fr)
MA (1) MA33531B1 (fr)
MX (1) MX2012003591A (fr)
MY (2) MY184074A (fr)
NZ (1) NZ597833A (fr)
PE (1) PE20121025A1 (fr)
PL (1) PL2483278T3 (fr)
PT (1) PT2483278E (fr)
RS (1) RS53164B (fr)
RU (2) RU2600927C2 (fr)
SG (1) SG10201405049RA (fr)
SI (1) SI2483278T1 (fr)
TW (1) TWI423980B (fr)
WO (1) WO2011036280A1 (fr)
ZA (1) ZA201202199B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598942A (en) 2009-07-27 2014-02-28 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
NZ599090A (en) * 2009-09-28 2014-02-28 Hoffmann La Roche Benzoxepin pi3k inhibitor compounds and methods of use
PE20121025A1 (es) * 2009-09-28 2012-08-06 Hoffmann La Roche Compuestos de benzoxazepina como inhibidores de la p13k
CN103096977B (zh) 2010-07-02 2017-02-15 吉利德科学公司 作为离子通道调节剂的稠杂环化合物
CA2825966A1 (fr) * 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Composes de benzoxazepine selectifs pour pi3k p110 delta et leurs methodes d'utilisation
TWI577670B (zh) 2011-05-10 2017-04-11 基利科學股份有限公司 充當離子通道調節劑之稠合雜環化合物
WO2012156379A1 (fr) 2011-05-13 2012-11-22 Universität Zürich Inhibiteurs de pik3/p110α pour la prévention de la resténose par application sous la forme d'un revêtement pour implant
NO3175985T3 (fr) 2011-07-01 2018-04-28
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
HK1206024A1 (en) * 2012-02-17 2015-12-31 F. Hoffmann-La Roche Ag Tricyclic compounds and methods of use therefor
NZ702244A (en) * 2012-06-08 2017-06-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
BR112014032346A2 (pt) 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
CN102775395A (zh) * 2012-07-12 2012-11-14 江苏七洲绿色化工股份有限公司 一种丙环唑的制备方法及丙环唑中间体
US9303046B2 (en) * 2012-08-07 2016-04-05 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
EP3404032B1 (fr) * 2013-03-13 2025-07-02 F. Hoffmann-La Roche AG Procédé de fabrication de composés de benzoxazépine
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
RU2018119749A (ru) * 2013-12-16 2018-11-09 Ф. Хоффманн-Ля Рош Аг Полиморфы 2-(4-(2-(1-изопропил-3-метил-1h-1,2,4-триазол-5-ил)-5,6-дигидробензо[f]имидазо[1,2-d][1,4]оксазепин-9-ил)-1h-пиразол-1-ил)-2-метилпропанамида, способы их получения и фармацевтические применения
SG11201607334YA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
SG11201708622UA (en) 2015-02-02 2017-11-29 Forma Therapeutics Inc 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
WO2016174616A1 (fr) * 2015-04-30 2016-11-03 Novartis Ag Dérivés de pyrazole tricycliques fusionnés utiles pour moduler des récepteurs farnésoïdes x
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
EP3314265B1 (fr) 2015-06-29 2019-07-24 H. Hoffnabb-La Roche Ag Méthodes de traitement avec du tasélisib
TW202108592A (zh) * 2015-07-02 2021-03-01 瑞士商赫孚孟拉羅股份公司 苯并氧氮呯噁唑啶酮化合物及其用途
US9643980B2 (en) 2015-07-02 2017-05-09 Genentech, Inc. Benzoxazepin oxazolidinone compounds and methods of use
US10065970B2 (en) 2015-09-08 2018-09-04 Genentech, Inc. Tricyclic PI3K inhibitor compounds and methods of use
US9721369B2 (en) * 2015-09-15 2017-08-01 Facebook, Inc. Systems and methods for utilizing multiple map portions from multiple map data sources
WO2017218950A1 (fr) 2016-06-17 2017-12-21 Forma Therapeutics, Inc. Indanes d'acide hydroxamique 2-spiro-5 et 6 utilisés en tant qu'inhibiteurs de hdac
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
MX2019003714A (es) 2016-09-29 2019-06-24 Bayer Cropscience Ag Novedosos derivados de imidazolilmetilo 5-sustituidos.
PL3851441T3 (pl) * 2016-12-15 2023-11-06 F. Hoffmann-La Roche Ag Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu
LT3589661T (lt) 2017-03-02 2024-02-12 Genentech, Inc. Adjuvantinis her2 atžvilgiu teigiamo krūties vėžio gydymas
EP4534148A3 (fr) 2017-04-28 2025-05-21 F. Hoffmann-La Roche AG Polymorphes et formes solides de (s)-2-((2-((s)-4-(difluorométhyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f!imidazo[1,2-d [1,4 oxazépin-9-yl)amino)propanamide, et procédés de production
MY203853A (en) * 2017-10-26 2024-07-22 Xynomic Pharmaceuticals Inc Crystalline salts of a b-raf kinase inhibitor
JP7456945B2 (ja) * 2018-05-30 2024-03-27 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 三環式誘導体を含む阻害剤、その製造方法、及び使用
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
WO2021088845A1 (fr) * 2019-11-04 2021-05-14 贝达药业股份有限公司 Composé imidazolidinone et son procédé de préparation et son utilisation
IL292592A (en) * 2019-11-04 2022-07-01 Betta Pharmaceuticals Co Ltd Imidazoline compound, process for its preparation and use
AU2020389670A1 (en) * 2019-11-25 2022-05-19 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof
CN117337290A (zh) * 2021-05-03 2024-01-02 山东轩竹医药科技有限公司 三并环类泛素特异性蛋白酶1抑制剂及其用途
CN117242078A (zh) * 2021-05-13 2023-12-15 贝达药业股份有限公司 咪唑烷酮类化合物的多晶型物、制备方法及其用途
CA3220273A1 (fr) 2021-05-28 2022-12-01 Genentech, Inc. Procede de preparation de composes de benzoxazepine oxazolidinone
CN120202205A (zh) * 2022-11-17 2025-06-24 微境生物医药科技(上海)有限公司 三并环类PI3Kα抑制剂及其制备方法和医药用途
CN116003280B (zh) * 2022-12-30 2024-11-19 合肥工业大学 一种芳基甲酰胺类化合物的光化学合成方法
WO2025082533A1 (fr) * 2023-10-21 2025-04-24 上海轶诺药业有限公司 Composés à cycle condensé, leur préparation et leur utilisation
WO2025237374A1 (fr) * 2024-05-16 2025-11-20 微境生物医药科技(上海)有限公司 Inhibiteur de pi3kalpha, son procédé de préparation et son utilisation pharmaceutique

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB8504702D0 (en) * 1985-02-23 1985-03-27 Zyma Sa Tricyclic compounds
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
FI943948A7 (fi) * 1992-12-28 1994-08-26 Eisai Co Ltd Heterosykliset hiilihappojohdannaiset
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
WO1997019087A1 (fr) * 1995-11-17 1997-05-29 E.I. Du Pont De Nemours And Company Heterocycles herbicides tricycliques
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
DE19908537A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908535A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908533A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908538A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
US7273880B2 (en) * 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
AU2001246494A1 (en) 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
RU2003126913A (ru) 2001-02-02 2005-03-10 Шеринг Корпорейшн (US) 3,4-дизамещенные циклобутен-1,2-дионы, как антагонисты хемокинового рецептора схс
TWI232863B (en) * 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
AU2003256650A1 (en) * 2002-07-19 2004-02-09 Pharmacia Corporation Substituted thiophene carboxamide compounds for the treatment of inflammation
CA2514241A1 (fr) * 2003-02-07 2004-08-19 Warner-Lambert Company Llc Derives d'oxazolidinones n-substitues par un noyau tricyclique, destines a etre utilises en tant qu'agents antibacteriens
TW200510356A (en) * 2003-08-01 2005-03-16 Takeda Chemical Industries Ltd Benzoxaepine compounds
US20050239767A1 (en) * 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
US7632833B2 (en) * 2004-07-01 2009-12-15 Merck & Co., Inc. Mitotic kinesin inhibitors
RU2403258C2 (ru) * 2004-10-07 2010-11-10 Бёрингер Ингельхайм Интернациональ Гмбх Тиазолилдигидроиндазолы
CA3052368A1 (fr) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines comme inhibiteurs de mek
US20070238718A1 (en) * 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
GB0610866D0 (en) * 2006-06-02 2006-07-12 Hammersmith Imanet Ltd Novel in vivo imaging compounds
WO2008014483A1 (fr) * 2006-07-28 2008-01-31 Alcan Packaging Flexible France Film co-extrudé avec de l'acide polylactique (pla) et un polymère éthylène/acétate de vinyle (eva)
US8877791B2 (en) 2006-08-04 2014-11-04 Beth Israel Deaconess Medical Center, Inc. Inhibitors of pyruvate kinase and methods of treating disease
US8779154B2 (en) * 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
NZ577719A (en) * 2006-12-29 2012-06-29 Abbott Gmbh & Co Kg Pyrazol-1-yl-aryl amides and their analogues and their pharmaceutical uses
AU2008302703B2 (en) 2007-09-19 2013-11-07 The Regents Of The University Of California Positron emission tomography probes for imaging immune activation and selected cancers
TWI443102B (zh) * 2008-03-31 2014-07-01 Genentech Inc 苯并哌喃及苯并氧呯ｐｉ３ｋ抑制劑化合物及其使用方法
JP5579724B2 (ja) * 2008-10-17 2014-08-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ホスファチジルイノシトール−３−キナーゼ（ｐｉ−３キナーゼ）阻害剤としてのテトラ−アザ−複素環
NZ599090A (en) * 2009-09-28 2014-02-28 Hoffmann La Roche Benzoxepin pi3k inhibitor compounds and methods of use
PE20121025A1 (es) * 2009-09-28 2012-08-06 Hoffmann La Roche Compuestos de benzoxazepina como inhibidores de la p13k

Also Published As

Publication number Publication date
RU2600927C2 (ru) 2016-10-27
CO6491026A2 (es) 2012-07-31
US20160052933A1 (en) 2016-02-25
US20110076292A1 (en) 2011-03-31
CR20120121A (es) 2012-06-01
RU2654068C1 (ru) 2018-05-16
IL239081A0 (en) 2015-07-30
US9670228B2 (en) 2017-06-06
PT2483278E (pt) 2014-03-05
US9198918B2 (en) 2015-12-01
DK2483278T3 (da) 2014-01-13
CN104744491B (zh) 2017-07-11
CN102762576A (zh) 2012-10-31
IL239081B (en) 2018-05-31
ECSP12011755A (es) 2012-05-30
JP2013505917A (ja) 2013-02-21
EP2711368A1 (fr) 2014-03-26
AU2010299816A1 (en) 2012-02-02
ES2570569T3 (es) 2016-05-19
US20130079331A1 (en) 2013-03-28
US8785626B2 (en) 2014-07-22
MY184074A (en) 2021-03-17
IL217558A (en) 2015-06-30
JP2014070075A (ja) 2014-04-21
TW201127844A (en) 2011-08-16
IL217558A0 (en) 2012-02-29
CA2772691C (fr) 2017-10-03
US20140288047A1 (en) 2014-09-25
CA2772691A1 (fr) 2011-03-31
ES2444779T3 (es) 2014-02-26
JP5625101B2 (ja) 2014-11-12
US20140058098A1 (en) 2014-02-27
CL2012000754A1 (es) 2012-09-07
US8343955B2 (en) 2013-01-01
AR078187A1 (es) 2011-10-19
RU2012117398A (ru) 2013-11-10
SG10201405049RA (en) 2014-10-30
US20170081341A1 (en) 2017-03-23
KR101428346B1 (ko) 2014-08-07
EP2711368B1 (fr) 2016-03-23
TWI423980B (zh) 2014-01-21
EP2483278A1 (fr) 2012-08-08
CN102762576B (zh) 2015-04-22
AU2010299816C1 (en) 2018-02-01
SI2483278T1 (sl) 2014-03-31
NZ597833A (en) 2014-01-31
AU2010299816B2 (en) 2015-11-12
RS53164B (sr) 2014-06-30
EP2845592A1 (fr) 2015-03-11
KR20120065431A (ko) 2012-06-20
HRP20140229T1 (hr) 2014-04-11
HK1211929A1 (en) 2016-06-03
US8242104B2 (en) 2012-08-14
US20120244149A1 (en) 2012-09-27
MY160064A (en) 2017-02-15
WO2011036280A1 (fr) 2011-03-31
HK1174629A1 (en) 2013-06-14
US9546178B2 (en) 2017-01-17
CN104744491A (zh) 2015-07-01
EP2483278B1 (fr) 2013-12-25
ZA201202199B (en) 2013-01-30
BR112012006807A2 (pt) 2020-11-03
MX2012003591A (es) 2012-04-19
PE20121025A1 (es) 2012-08-06
JP5540101B2 (ja) 2014-07-02
US8586574B2 (en) 2013-11-19
PL2483278T3 (pl) 2014-05-30

Similar Documents

Publication Publication Date Title
MA33531B1 (fr) Composés de benzoxazépine inhibiteurs de pi3k et leurs procédés d'utilisation
MA31358B1 (fr) Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA31419B1 (fr) Derives de pyridine
TN2010000052A1 (fr) Derives de pyrazole et leur utilisation comme inhibiteurs de raf
MA32903B1 (fr) Inhibiteurs de proteine-kinases
MX2009009786A (es) Inhibidores de la via de hedgehog.
TN2009000329A1 (fr) DERIVES DE 2-AMINO-5,7-DIHYDRO-6H-PYRROLO[3,4-d]-PYRIMIDINE SERVANT D'INHBITEURS DE HSP-90 POUR LE TRAITEMENT DU CANCER
SMT201300109B (it) Imidazopiridazincarbonitrili utili come inibitori di chinasi
HRP20040686B1 (hr) Novi heterocikliäśki spojevi koji djeluju kao inhibitori beta-laktamaza
TN2012000062A1 (en) Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer
MA32904B1 (fr) Composes de purine
MA35643B1 (fr) Inhibiteur de cetp d'oxazolidinone bicyclique condensée
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
NI200900183A (es) Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer.
MA34760B1 (fr) Composés et leurs utilisation
MA32563B1 (fr) Dabigatran pour cathétérisme cardiaque de chirurgie percutanée
MA31873B1 (fr) Inhibiteurs de la peptide déformylase
WO2011041304A3 (fr) Agents antipaludiques inhibiteurs de la dihydro-orotate déshydrogénase
EA201991916A1 (ru) 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ
NZ592927A (en) PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
TN2016000253A1 (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis.
UY31824A (es) Nuevos compuestos
MA35010B1 (fr) Inhibiteurs de la peptide déformylase